Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib gel in sporadic nodular basal cell carcinoma
NCT02828111Phase 2Completed
- Sponsor
- PellePharm
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of patidegib in basal cell carcinoma (BCC) (8 arms), sponsored by PellePharm. Primary endpoints: Treatment-emergent Adverse Events at 12 weeks and Percent Change From Baseline in GLI1 mRNA Levels at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
patidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02828111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828111.